COMMUNIQUÉS West-GlobeNewswire

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
24/02/2026
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled [...]
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
24/02/2026
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technology NEW YORK [...]
Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics
24/02/2026
New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
Alkeus Pharmaceuticals Announces Presentation of Investigational Oral Gildeuretinol Data During the 49th Annual Meeting of the Macula Society Being Held February 25-28
24/02/2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that results [...]
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
24/02/2026
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
24/02/2026
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo [...]
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02/2026
Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files provisional patent [...]
NewGen Provides Recap of Strategic Progress as Diversification Fuels Success, Positions Company for Breakout Year
24/02/2026
Strategic transformation establishes strong foundation with US$28 million in Net Assets and a high-potential, multi-sector portfolio BANGKOK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or [...]
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
24/02/2026
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may [...]
Centre for Neuro Skills Physician-Researcher Dr. Brent Masel to Receive NABIS Legends Award for Lifetime of Contributions to Traumatic Brain Injury Care
24/02/2026
North American Brain Injury Society honors the pioneering neurorehabilitation researcher and clinician at the NABIS 18th Annual Conference on Brain Injury, March 11–13, 2026, Hilton Arlington National Landing, Arlington [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24/02/2026
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating [...]
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact [...]
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026
Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds Additional capital further supports clinical development of ALV [...]
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
24/02/2026
Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML SAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose [...]
Full year Trading Update and Notice of Results
24/02/2026
Revenues at the upper end of guidance and pivot to EBITDA profitability - expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 [...]
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
24/02/2026
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support [...]
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health [...]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory [...]

Pages